NYSE · LLY
Healthcare · Drug Manufacturers - General
$1,174.61
Down-$3.24 (-0.28%)
Updated Aug 31, 2026, 4:54 AM
SID Score
6.4/10
Composite research score
Smart Money
45/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LLY closed at $1,174.61 after 20 trading sessions, up 4.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
| Aug 21, 2026 | $1,232.00 | $1,271.22 | $1,230.00 | $1,255.40 | 2.5M |
| Aug 20, 2026 | $1,274.13 | $1,280.28 | $1,243.2301 | $1,244.40 | 2.62M |
| Aug 19, 2026 | $1,245.81 | $1,292.65 | $1,240.54 | $1,280.34 | 4.54M |
| Aug 18, 2026 | $1,200.00 | $1,228.47 | $1,194.01 | $1,225.73 | 2.51M |
| Aug 17, 2026 | $1,175.20 | $1,198.52 | $1,163.50 | $1,183.16 | 1.81M |
| Aug 14, 2026 | $1,194.01 | $1,199.00 | $1,171.1956 | $1,180.16 | 2.27M |
| Aug 13, 2026 | $1,238.30 | $1,240.10 | $1,206.00 | $1,209.00 | 1.93M |
| Aug 12, 2026 | $1,201.73 | $1,226.50 | $1,191.08 | $1,220.28 | 1.94M |
| Aug 11, 2026 | $1,230.65 | $1,237.9999 | $1,209.53 | $1,215.02 | 2.11M |
| Aug 10, 2026 | $1,185.01 | $1,231.94 | $1,184.405 | $1,231.94 | 3.01M |
| Aug 7, 2026 | $1,188.00 | $1,196.80 | $1,161.2001 | $1,185.71 | 2.9M |
| Aug 6, 2026 | $1,196.55 | $1,230.88 | $1,173.50 | $1,191.94 | 3.42M |
| Aug 5, 2026 | $1,174.00 | $1,216.94 | $1,138.4301 | $1,169.86 | 6.45M |
| Aug 4, 2026 | $1,117.38 | $1,135.83 | $1,109.16 | $1,115.68 | 4.1M |
| Aug 3, 2026 | $1,152.00 | $1,161.9403 | $1,109.15 | $1,121.36 | 2.93M |
The latest Smart Investors Daily articles mentioning LLY.
LLY research
Company profile and research snapshot.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Citigroup | Buy | — |
| Jul 14, 2026 | Bernstein | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its
SeekingAlpha · Aug 27, 2026
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here for more.
ChartMill · Aug 26, 2026
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Benzinga · Aug 26, 2026
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company shares closed at $1,172.86, reflecting a daily decline of 1.66% per SID market data. Despite the near-term pullback, the stock has demonstrated positive momentum across broader timeframes, gaining 1.7% over the past month, 6.3% over three months, and 13.65% over the trailing twelve months. Technically, LLY trades below its 50-day moving average of $1,186.84 but remains well above its 200-day moving average of $1,055.82, suggesting the longer-term uptrend remains intact. The 14-day relative strength index sits at 40.1, approaching oversold territory without yet triggering a classic oversold signal. The stock carries a beta of 0.369 according to SID market data, indicating significantly lower volatility than the broader market. Average daily trading volume stands at approximately 3.8 million shares, supporting a market capitalization of roughly $906.5 billion, positioning Eli Lilly among the largest healthcare companies globally.
Eli Lilly trades at a price-to-earnings ratio of 49.16, reflecting a substantial premium relative to the broader healthcare sector, per SID market data. The PEG ratio stands at 1.47, suggesting the valuation is more reasonable when accounting for the company's projected earnings growth trajectory, though it still exceeds the commonly referenced fair-value threshold of 1.0. The price-to-book ratio registers at 38.04, an elevated figure that underscores the market's pricing of Eli Lilly's intangible assets, particularly its pharmaceutical pipeline and brand value. According to SEC filings, the company offers a dividend yield of approximately 0.59%, a modest payout that reflects management's preference for reinvesting capital into research and development. The current valuation metrics collectively indicate that the market has priced in significant future growth expectations for Eli Lilly, largely driven by its GLP-1 receptor agonist franchise and broader pipeline developments across multiple therapeutic areas.
Eli Lilly's composite smart money score stands at 45 out of 100, registering a neutral signal per SID market data. Institutional ownership receives the highest component score at 25 out of 25, indicating maximum confidence from large fund managers and reflecting broad-based accumulation among major asset managers. The insider activity component scores 4.1 out of 25, with SEC Form 4 filings revealing 14 insider transactions over the past 90 days, comprising 9 purchases and 5 sales. The net buying bias among insiders suggests a degree of internal confidence in the company's forward trajectory. Dark pool activity scores 9.2 out of 25, indicating moderate levels of off-exchange institutional trading. Congressional trading activity registers at 6.4 out of 25 according to disclosure filings, reflecting limited but notable legislative interest. The divergence between perfect institutional scores and lower insider and dark pool readings creates the neutral composite signal, suggesting mixed positioning among different categories of informed market participants rather than a unified directional conviction.
Eli Lilly has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter reported on August 5, the company posted earnings per share of $8.38 against a consensus estimate of $6.01, representing a surprise of $2.37 or approximately 39.4%. The prior quarter saw EPS of $8.55 versus the $6.85 estimate, a $1.70 positive surprise. The quarter before that produced EPS of $7.54 against a $6.96 estimate, beating by $0.58. The pattern of accelerating beat magnitudes highlights strengthening operational execution. Looking ahead, analysts estimate EPS of $8.84 for the upcoming quarter with results expected on August 6, per analyst estimates. The trajectory of rising absolute earnings figures — from $7.54 to $8.55 over three consecutive quarters — demonstrates robust revenue growth driven primarily by the company's diabetes and obesity treatment portfolio.
Wall Street consensus on Eli Lilly remains unanimously bullish, with all five most recent analyst actions reiterating positive ratings, per SID consensus data. On August 7, Truist Securities maintained its Buy rating, while Wells Fargo and Cantor Fitzgerald both reiterated Overweight ratings on August 6, following the company's latest earnings release. Citigroup reaffirmed its Buy recommendation on July 15, and Bernstein maintained its Outperform rating on July 14, according to Wall Street analyst reports. Notably, none of the recent rating actions represented upgrades or downgrades, as each firm maintained its previously established positive stance. The consistency of these reiterations across five separate firms — spanning both bulge-bracket and independent research houses — reflects broad institutional conviction in Eli Lilly's growth narrative. The clustering of reiterations around the early August earnings period suggests that the company's strong quarterly results reinforced existing investment theses rather than prompting any meaningful reassessment of the fundamental outlook among coverage analysts.
The latest Smart Investors Daily articles mentioning LLY.
